Prevention of type 2 diabetes mellitus;Prevenção do diabetes mellitus tipo 2

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 2, 2006, Pages 239-249

  Lyra, Ruy ^a,b   Oliveira, Mônica ^a   Lins, Daniel ^a   Cavalcanti, Ney ^a  

^a UNIVERSIDADE DE PERNAMBUCO   (Brazil)

^b NONE   (Brazil)

Author keywords

Intervention; Lifestyle; Pharmacological therapy; Prevention; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

BARIATRIC SURGERY; HUMAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; RISK FACTORS;

EID: 33744455714     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000200010     Document Type: Review

References (76)

1. Wild S, Roglic G, Green A, Sicree S, King H. Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047.
2. World Health Organization. The World Health Report 2003. Geneva:World Health Organization; 2003.
3. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28(9):2130-5.
4. American Diabetes Association. Economics costs of diabetes in US in 2002. Diabetes Care 2003;26:917-32.
5. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27(1):17-20.
6. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
7. Chan JM, Rimm EB, Colditz Stampfer MJ, Willet WC. Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-9.
8. Ramachandran A, Snehalatha C, Shobana R, Vidyavathi P, Vijay V. Influence of life-style factors in development of diabetes in Indians - scope for primary prevention. J Assoc Phys India 1999;47:761-3.
9. Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention; the case for action. Int J Obes Relat Metab Disord 2002;26:425-36.
10. Golay A, Masciangelo ML. Burden of obesity: from epidemic to costs. Rev Med Suisse 2005;1(12):807-10, 813.
11. Oster G, Edelsberg J, O'Sullivan AK, Thompson D. The clinical and economic burden of obesity in a managed care setting. Am J Manag Care 2000;6(6):681-9.
12. Mayer-Davis EJ, Costacou T. Obesity and sedentary lifestyle: modifiable risk factors for prevention of type 2 diabetes. Curr Diab Rep 2001;1(2):170-6.
13. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17(9):961-9.
14. Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, et al. Fruit and vegetable intake and population glycosylated haemoglobin levels: the EPIC-Norfolk Study. Eur J Clin Nutr 2001;55(5):342-8.
15. Van Dam R, Rimm E, Willett W, Stampfer M. Dietary patterns and risk for type 2 diabetes mellitus in US men. Ann Intern Med 2002;136:201.
16. Choi HK, Willett WC, Stampfer MJ, Rimm E, Hu FB. Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study. Arch Intern Med 2005;165(9):997-1003.
17. Henriksson J. Effects of physical training on the metabolism of skeletal muscle. Diabetes Care 1992;15:1701-11.
18. Mcauley K, Williams S, Mann J, Goulding A, Chisholm A, Wilson N, et al. Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes Care 2002;25:445-52.
19. Annuzi G, Riccardi G, Capaldo S, Kaijser L. Increased insulin-stimulated glucose uptake by exercised human muscles one day after prolonged physical exercise. Euro J Clin Invest 1991;21:6-12.
20. Zawadzki JK, Bogardus C, Foley JE. Insulin action in obese noninsulin-dependent diabetics and in their isolated adipocytes before and after weight loss. Diabetes 1987;36:227-36.
21. Burchfield CM, Sharp DS, Curb JD, Rodriguez, Hwang LJ, Marcus EB, et al. Physical activity and incidence of diabetes: The Honolulu Heart Program. Am J Epidemiol 1995;141:360-8.
22. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992;268:63-7.
23. Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG. Prospective study of risk factors for development of non-insulin dependent diabetes in middle-aged British men. Br Med J 1995;310:560-4.
24. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991;325(3):147-52.
25. Lynch J, Helmrich SP, Lakka TA, Kaplan GA, Cohen RD, Salonen R, et al. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Arch Intern Med 1996;156:1307-14.
26. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995;310:555-9.
27. Uchimoto S, Tsumura K, Hayashi T, Suematsu C, Endo G, Fujii S, et al. Impact of cigarette smoking on the incidence of type 2 diabetes mellitus in middle-aged Japanese men: the Osaka Health Survey. Diabet Med 1999;16:951-5.
28. Shimokata H, Muller DC, Andres R. Studies in the distribution of body fat. III. Effects of cigarette smoking. JAMA 1989;261:1169-73.
29. Frati AC, Iniestra F, Ariza CR. Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factors. Diabetes Care 1996;19:112-8.
30. Janzon L, Berntorp K, Hanson M, Lindell SE, Trell E. Glucose tolerance and smoking: a population study of oral and intravenous glucose tolerance tests in middle-aged men. Diabetologia 1983;25:86-8.
31. Manson JE, Ajani UA, Liu S, Nathan DM, Hennekens CH. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med 2000;109:538-42.
32. Wannamethee SG, Shaper AG, Perry IJ; British Regional Heart Study. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 2001;24:1590-5.
33. Ramachandran A, Snehalatha C, Shobana R, Vidyavathi P, Vijay V. Influence of life-style factors in development of diabetes in Indians - scope for primary prevention. J Assoc Physicians India 1999;47:761-3.
34. Krause N. Stress and diabetes mellitus in later life. Int J Aging Hum Dev 1995;40:125-43.
35. Eriksson KF, Lindgarde F. Prevention of type 2 diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;34:891-8.
36. Eriksson K-F, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998;41:1010-6.
37. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. The Da Qing IGT, Diabetes Study. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997;20:537-44.
38. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
39. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
40. Kazua Y, Tongo T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2005;28:2780-6.
41. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-9.
42. Keen H, Jarrett RJ, Ward JD, Fuller JH. Borderline diabetics and their response to tolbutamide. Adv Metab Disord 1973;2(suppl 2):521-31.
43. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M; The STOP-NIDDM Trial Research Group. The STOP-NIDDM Trial. An international study on the efficacy of an a-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary data. Diabetes Care 1998;21:1720-5.
44. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072-7.
45. Hanefeld M, Josse RG, Gomis R, Karasik A, Laakso M, Chiasson JL. Efficacy of acarbose to prevent type 2 diabetes is different in subgroups of subjects with impaired glucose tolerance: The STOP-NIDDM trial. Diabetologia 2002;45:S104-5.
46. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
47. Jarrett RJ, Keen H, Fuller JH, McCartney M. Treatment of borderline diabetes: controlled trial using carbohydrate restriction andphenformin. Br Med J 1977;2:861-5.
48. Jarrett RJ, Keen H, Fuller JH, McCartney M. Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia 1979;16:25-30.
49. Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med 1999;16:477-81.
50. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996;19:920-6.
51. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.
52. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, et al; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6.
53. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280-5.
54. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-9.
55. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
56. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.
57. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004;27:247-55.
58. Savage PH, Pressel SL, Curb D, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med 1998;158:741-75.
59. Fletcher A, Amery A, Birkenhager W, Bulpitt C, Clement D, de Leeuw P, et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1991;9:225-30.
60. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BHR, et al. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.
61. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy: the Captopril Prevention Project (CAPP) randomized trial. Lancet 1999;35:611-6.
62. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
63. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principle results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
64. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertension 2002;20:1879-86.
65. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
66. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9.
67. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31.
68. Freeman DJ, Norrie J, Sattar N, Neely DG, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
69. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 2003;26:2713-21.
70. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-16.
71. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
72. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, et al. Peroxisome proliferators-activated receptor ligand Bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004;109:2197-202.
73. Manson JE, Rimm EB, Colditz GA, Willett WC, Nathan DM, Arky RA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 1992;2:665-73.
74. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study. Obesity Res 1999;7:477-84.
75. Sjöström CD, Peltonen M, Wedel H, Sjöström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36:20-5.
76. Pories WJ, MacDonald KG, Morgan EJ, Sinha MK, Dohm GL, Swanson MS, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 1992;55:582S-5.